Background Lupus nephritis (LN) is the most serious complication of SLE. Interstitial fibrosis is the dominant pathological ...

Objective Peer mentoring has been shown to be an effective intervention for chronic conditions with evidence to suggest that ...

Glucocorticoids represent the most potent class of anti-inflammatory drugs. However, their anti-inflammatory mode of action has been incompletely understood. Recent insights have revealed a key role ...

Objective Celastrol is a bioactive constituent extracted from Tripterygium wilfordii (thunder god vine). It has been demonstrated to have a therapeutic effect on experimental disease models for ...

CD19-directed chimeric antigen receptor (CAR) T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for patients with autoimmune diseases.

Objective To evaluate the effect of early belimumab administration on disease progression in patients with early active SLE. Methods This multicentre observational study included patients with early ...

Objective Small fibre neuropathy (SFN) is an under-recognised complication of SLE that contributes to chronic pain and reduced quality of life. We assessed the utility of corneal confocal microscopy ...

Background and aims Background: SLE is difficult to diagnose because of the diverse manifestations occurring over time and across care sites. Electronic health records (EHR) present a rich source of ...

Objective To assess the efficacy and toxicity of the Lupus-Cruces Nephritis (LCN) protocol compared with standard of care (SOC) with cyclophosphamide (CYC) or mycophenolate in patients with lupus ...

Objective Lupus nephritis (LN) is one of the most severe manifestations of SLE; however, we know little about the lived experience of LN. This research investigates patient experiences and ...